Affordable Access

deepdyve-link
Publisher Website

Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.

Authors
  • Chen, Chien-Liang
  • Chen, Nai-Ching
  • Liang, Huei-Lung
  • Hsu, Chih-Yang
  • Chou, Kang-Ju
  • Fang, Hua-Chang
  • Lee, Po-Tsang
Type
Published Article
Journal
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Publication Date
Jul 01, 2015
Volume
100
Issue
7
Pages
2784–2792
Identifiers
DOI: 10.1210/jc.2015-1259
PMID: 25955225
Source
Medline
License
Unknown

Abstract

Denosumab allows for supra-physiologic doses of calcitriol resulting in decreased parathyroid secretion and parathyroid hyperplasia. Supervised administration and weekly laboratory and clinical monitoring of serum calcium are recommended during the first month to prevent hypocalcemia.

Report this publication

Statistics

Seen <100 times